Objective. To investigate the frequency and risk factors of postoperative complications in RA patients treated with abatacept (ABA).
Introduction
Surgery, and particularly orthopaedic surgery, is frequent in RA patients. Despite recent data indicating a decline in the rates of hand and foot surgery over the last decades, incidence of arthroplasty remains stable in patients with RA, with a 10-year cumulating incidence reaching 11.9%, according to a recent estimation [1] . The risk of postoperative complications has been thoroughly studied after arthroplasty procedures, and is higher in RA than in non-inflammatory disorders such as OA, especially regarding infections [2, 3] . Immunosuppressive medications used in RA contribute to this risk and their perioperative management is thus a critical issue [4] . If biologics were to increase the risk of postoperative infections, withholding them before surgery would expose patients to RA flares in the perioperative period requiring higher doses of corticosteroids, which are known to be associated with an increased risk of infections and delayed wound healing [5] .
The perioperative risk of RA patients treated with antiTNFa use has been extensively investigated, and studies indicate a higher risk of surgical site infections (SSIs) [6] . The ACR recommends withholding anti-TNFa for at least 1 week before surgery [7] . Other guidelines recommend withholding therapy for 25 half-lives of the drug [8, 9] . To date, few data are available regarding the safety of surgery in RA patients treated with rituximab (RTX) or tocilizumab (TCZ). Data from the French AutoImmunity and Rituximab (AIR) registry indicate a rate of complication of about 8.5% for 140 surgeries, mostly infections in RA patients treated with RTX [10] . In another study on 161 surgeries in 122 TCZ-treated patients, 14.3% entailed complications (20 delayed wound healing, 3 SSIs) [11] . Finally, data available on abatacept (ABA) in the perioperative period are scarce.
Unlike randomized controlled trials, which involve selected patient populations with a short time of exposure to the drugs, observational studies provide long-term safety and efficacy data of real life RA patients treated in routine care, allowing estimation of the risk of surgical complications associated with the use of biologics [12] . We used the French Orencia and RA (ORA) registry to investigate the risk of complications in RA patients undergoing surgery while treated with ABA and to identify baseline or preoperative factors associated with an increased risk of complications after surgery in ABA-treated RA patients.
Methods

Study population
The methodology of the ORA registry, an ongoing nationwide prospective cohort study investigating the long-term safety and efficacy of i.v. ABA for treating RA, has been described before [13] . Patients were included in this study if they underwent surgery while treated with ABA. For each surgery, the date of the surgery had to be known, the surgery had to be performed while the patient was exposed to the drug, that is, during the 3 months after an infusion of ABA, and patients must have one followup visit at least 3 months after surgery, and at least 1 year after an arthroplasty. This period of 3 months is usually used to define the at-risk period for serious infections in patients treated with biologics [13] , and is consistent with the half-life of ABA, which may be up to 25 days [14] . The registry was approved by the French authorities (Comite Consultatif sur le Traitement de l'Information en Matiè re de Recherche dans le Domaine de la Santé and Commission Nationale de l'Informatique et des Libertes). All participants gave their written informed consent. Due to the observational nature of this study, no additional approval to perform it was required.
Surgical complications
Postoperative complications were defined as local (delayed wound healing, SSIs) or general (hospital acquired infection except SSIs, venous thromboembolism occurring within 35 days [15] and death within 90 days). A venous thromboembolism was defined as a pulmonary embolism or a deep vein thrombosis. In accordance with the 1992 Centres for Disease Control definitions [16] , SSIs were defined as infections occurring within the first 30 days after any surgery or the first year in the case of arthroplasty, and as superficial or deep if involving tissue above or below the aponeurosis, respectively. A delayed wound healing was defined as an abnormal healing process entailing a delayed wound closure as judged by the surgeon or the rheumatologist, in the absence of SSIs. A nosocomial infection was defined as an infection not present in the first 2 days after admission and occurring during hospital stay until the first 2 days following hospital discharge. A surgery followed by a postoperative complication was defined as a surgery with complication. If one patient underwent several surgeries, he was considered as a patient with complication if at least one surgery was described as complicated.
Data collection
In order to identify factors associated with postoperative complications in RA patients treated with ABA, the following baseline data were collected for each patient: demographics (age; sex), comorbidities (main cardiovascular risk factors including smoking status and diabetes mellitus; cardiac insufficiency; chronic lung disease; chronic kidney disease; previous severe, chronic or recurrent infection; history of cancer) and characteristics of the disease (disease duration; extra articular involvement; DAS28; positivity for RF; or anti-CCP antibodies). We also collected serum gammaglobulins and IgG levels, and previous and ongoing treatments at baseline (corticosteroids; DMARDs; biologics) and their dosages.
We distinguished different types of surgery, between orthopaedic surgery (with or without arthroplasty; surgery of the upper or the lower limb; spine surgery), abdominal surgery and other surgery. Regarding orthopaedic procedures, we defined an RA-related surgery as a surgery whose indication was related to a joint damage specifically attributable to RA. For each surgery, we collected the following preoperative data from the last follow-up visit scheduled in the ORA registry preceding the surgery: duration of ABA treatment (i.e. time since initiation), time between the last ABA infusion and the time of surgery, DAS28, ongoing treatments (corticosteroids, DMARDs) and their dosages. For all surgeries, each participating centre was contacted by E-mail to confirm and/or complete with the referent rheumatologist the data of each surgery, the occurrence and type of postoperative complications and the time between the last infusion and surgery.
Statistical analysis
Data were described as the number (percentage) of patients and surgeries, and mean (S.D.) (or median and interquartile range or range in the case of small sample size). Baseline data for patients with and without complications and preoperative data for surgeries with and without complications were compared. Each surgery was considered individually even if one patient experienced several surgeries during the follow-up. Quantitative variables were compared by Student's unpaired t test (or the MannWhitney test in cases of small sample size), and qualitative variables were compared with the chisquare test (or Fisher's exact test). Factors associated with the risk of postoperative complications and reaching a P < 0.10 in univariate analysis were included in a multivariate logistic regression. Statistical analyses were performed using GraphPad Prism software (version 6.0: GraphPad Software, Inc., La Jolla, CA, USA) and SAS (version 9.3; SAS Institute Inc., Cary, NC, USA) for multivariate analysis. A P < 0.05 was considered significant.
Results
Characteristics of patients and surgeries
The ORA registry recruited 1012 RA patients between June 2008 and April 2010. Among them, we identified 333 patients (32.5%) who underwent 462 surgeries, of which 199 were excluded from further analyses (17 nonsurgical procedures, 6 surgeries with no data available on the procedure, 175 surgeries performed >3 months after an ABA infusion and 1 surgery was reported twice in the database). Finally, the analysis included 263 surgeries in 205 patients (20.3%). Their baseline characteristics are summarized in Table 1 .
Patients with surgery were older than those without surgery [60.2 (11.9) vs 57.6 (14.0) years, P = 0.01] and their disease duration at baseline was longer [14.8 (10.1) vs 12.6 (9.3) years, P < 0.0001] ( Table 1) . A higher proportion of patients with surgery received corticosteroids at baseline (81.0% vs 73.0%, P = 0.02), but their mean daily dosage of corticosteroids did not differ from the patients without surgery at baseline. There was no difference regarding the type and number of biologics patients with or without surgery received before ABA.
Surgeries were performed after a mean treatment duration of 17.4 (12.8) months (median: 15.5, range: 0.456.4 months) from the first ABA infusion. The mean time between surgery and the last ABA infusion was 5.3 (3.2) weeks (median: 5.9, range: 0.312.0 weeks; 225 available data). As expected, orthopaedic surgeries represented the majority of the procedures (66.9%, n = 176), including 54 (20.5%) arthroplasties. RA-related surgery concerned 109 procedures (41.4%) in 95 patients (46.3%), representing 9.3% of patients of the whole registry. Preoperative DAS28 was higher before RA-related surgeries than other surgeries [4.11 (2.13) vs 3.30 (1.22), P = 0.0005], and the mean time between surgery and the last ABA infusion was longer in the case of RA-related surgery [6.9 (4.5) (range: 0.611.0) vs 5.1 (3.2) (range: 0.312.0) weeks, P = 0.0007]. There was no betweengroup difference regarding the other preoperative characteristics.
Postoperative complications
Nineteen surgeries (7.2%) entailed complications in 19 patients (9.3%), namely 7 delayed wound healing (36.8% of all complications), 6 SSIs (31.6%), 4 nosocomial infections (21.1%; 2 pulmonary infections and 2 urinary tract infections) and 2 thromboembolic events (10.5%; 1 deep venous thrombosis and 1 pulmonary embolism). No death was reported.
Factors associated with postoperative complications
The baseline characteristics of patients with and without complications are shown in Table 2 . Although more patients with complications were current or former smokers (31.6% vs 18.4%), there was no significant difference between the two groups regarding comorbidities and previous or associated treatments. In 16 (7.8%) patients, the surgery was performed during the first 3 months of treatment with ABA-a period during which the biologic received just before ABA might influence the risk of complications. A complication occurred in six (37.5%) patients, and the last biologic did not affect the risk of complications in our study.
The characteristics of surgeries with and without complications are shown in Table 3 . The median time between the last infusion of ABA and surgery was similar in the two groups A higher rate of complications was found after orthopaedic procedures compared with other procedures (9.7% vs 2.3%, P = 0.02), as shown in Table 4 . This involved particularly surgeries of the lower limb (11.5% vs 4.4%, P = 0.049) and surgeries of the foot or ankle (14.0% vs 5.7%, P = 0.059). Finally, spine surgery or total joint replacement was not associated with a higher risk of complications.
In multivariate analysis, orthopaedic procedures were associated with a higher risk of complications (P = 0.049), compared with other kinds of surgery. The duration of treatment with ABA at the time of surgery (i.e. the time between the first ABA infusion and the surgery) was significantly associated with postoperative complications in multivariate analysis, with a decreased risk in patients treated for a longer period (P = 0.03; Table 5 ).
Discussion
To our knowledge, except for one report of eight orthopaedic surgeries in RA patients treated by ABA [17] , this is the first study investigating the perioperative risk associated with ABA treatment in routine care. In the ORA registry, the rate of postoperative complications is evaluated at 6.7% (8.9% of patients). Orthopaedic surgeries, especially those involving the lower limbs, and corticosteroid dose were associated with a higher risk of complication but the association with corticosteroid dose did not remain significant in multivariate analysis. In this study, a shorter duration of treatment with ABA was the main factor associated with postoperative complications and the time between ABA withdrawal and surgery (around 6 weeks) was the same in the patients with and without complications.
The higher risk of complications after orthopaedic surgery is well described in RA. Compared with patients with OA, patients with RA are at higher risk of dislocation following total hip replacement and early revision after total knee replacement [2]. They are also exposed to an increased risk of infection following arthroplasty [3, 18] . Thus, in our study, the association between orthopaedic procedures and complications is probably not related to ABA treatment. Besides, it loses its statistical significance in multivariate analysis. These comments also apply to the slightly higher risk identified with surgeries of the foot or ankle, which may entail more complications in RA than the other types of orthopaedic procedures regardless of medical treatment [19] . In this study, half of the complications were infections. However, except for corticosteroid dosage, no difference was found between complicated and non-complicated patients regarding comorbidities usually associated with a higher risk of infections, such as diabetes mellitus, chronic lung disease or disease activity [20] . Recently, older age, history of previous serious or recurrent infections or a lower number of anti-TNFa treatments has been identified as predictive factors of severe infections with ABA [13] . None of these factors were associated with the risk of complications in our study. Furthermore, despite its known association with postoperative complications after any surgery [21] and a higher proportion of smokers in the complicated group in our study, smoking status was not identified as a predictive factor of complications. This may be due to the lack of distinction between current and former smokers in the ORA registry, but we could not exclude that this study was underpowered to detect it.
The risk of postoperative complications ranges from 2.0 to 12.5% in RA patients treated with anti-TNFa [4] . In a study using the same methodology as the present study, it has been previously estimated in the AIR registry that 8.5% of surgeries entailed complications in patients treated with rituximab [10] . This rate reaches 12.4% with TCZ in a previous study [11] . Moreover, the vast majority of the patients included in the present study received MTX at the last visit preceding surgery. Grennan et al. [22] reported previously that the rate of complications in RA patients treated with MTX could vary from 2.0% if the treatment was maintained at the time of surgery, to 15% if it was discontinued 2 weeks before surgery. Given the variability in these results, which may be explained by the heterogeneity in the definitions of complications used in the different studies, comparison is difficult-especially regarding methotrexate. At least, the risk of surgery with ABA does not seem higher than with the other biologic DMARDs.
The main factor associated with the risk of complications in our study was a shorter duration of treatment with ABA. This result has already been found with RTX in the AIR registry [10] and is probably related to a healthy drug survivor effect (the patients prone to complications had previously discontinued the drug because of adverse events or inefficacy, while the healthy patients who tolerate the drug usually maintain the treatment) and should thus be interpreted with caution. However, a previous study did not find this association in RA patients treated with TCZ and undergoing surgery [11] . Regarding anti-TNFa, a shorter duration of treatment has already been associated with serious infections, but not in the specific context of surgery [23, 24] . Moreover, the gradual reduction of corticosteroids under ABA could explain the finding that patients with complications had higher doses of corticosteroids, because they underwent surgery earlier after the initiation of ABA than patients without complications. Hence, higher corticosteroid dosage might be one of the main determinants of postoperative complications in our study. However, there was no difference in the preoperative disease activity between the two groups, and corticosteroid doses were not significantly associated with complications in multivariate analysis. The mean time between the last infusion of ABA and the surgery was short, 6.6 (3.9) weeks, and did not differ between the groups. Interestingly, it is shorter than the time currently advised by the French Society of Rheumatology, which is 8 weeks. Unfortunately, we cannot determine the influence of emergency surgeries on this time since the ORA Registry database did not provide information on the emergency or elective nature of surgeries. However, this result encourages reconsideration of the current recommendations for decreasing the time between ABA withdrawal and surgery to 6 weeks.
The absence of a control group is one of the main limitations of our study. Indeed, it does not allow comparison with DMARDs or other biologics. However, the rate of complications after surgery was calculated with the same methodology in our RTX registry and reached 8.5% of the surgeries with RTX vs 6.7% with ABA in this study. The observational design inherent in registries is also a weakness since we cannot determine the safest minimal time between the withholding of ABA and the surgery, which is needed for guidelines. Indeed, our results only provide an indication that this time did not strongly influence the risk of complications, but the small number of complications in the present study, even though reassuring, precludes any formal conclusion. Albeit useful, these results call for further investigations.
Another limitation is the retrospective design of our study, which causes a significant risk of missing data. However, each participating centre was contacted to collect missing data, with an excellent response rate of about 80%. Moreover, the under-reporting bias might mainly impact non-complicated surgery, leading to an overestimation of the risk of postoperative complications rather than an underestimation. Finally, the preoperative data were collected from the last routine visit before surgery, which could be scheduled up to 6 months before the surgery. We did not have access to data at the exact time of the surgery or at the time ABA was stopped, and this could lead to data imprecision as the DAS28 or corticosteroid dosage could change within this period.
In conclusion, we found a rate of postoperative complications of 6.7% in RA patients treated with ABA. This risk may be higher in the case of orthopaedic surgery, especially after foot or ankle procedures. The main factor associated with complications is a shorter time after initiation of ABA, which may be related to a healthy drug survivor effect. In our study, the median time between surgery and the last infusion of ABA was short, 56 weeks, and did not influence the rate of postoperative complications.
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